PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Negative EBIT growth while TRAW is at 0.30%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.64%
Negative operating income growth while TRAW is at 0.30%. Joel Greenblatt would press for urgent turnaround measures.
-15.16%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
2.78%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.78%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
19.07%
Slight or no buybacks while TRAW is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
19.07%
Slight or no buyback while TRAW is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-16.01%
Dividend reduction while TRAW stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-25.31%
Negative OCF growth while TRAW is at 5.12%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-30.01%
Negative FCF growth while TRAW is at 5.12%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2395.20%
Negative 10Y OCF/share CAGR while TRAW stands at 99.99%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
87.33%
5Y OCF/share CAGR at 75-90% of TRAW's 99.90%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
68.32%
3Y OCF/share CAGR at 50-75% of TRAW's 99.47%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-1414.90%
Negative 10Y net income/share CAGR while TRAW is at 99.96%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.17%
Positive 5Y CAGR while TRAW is negative. John Neff might view this as a strong mid-term relative advantage.
80.18%
3Y net income/share CAGR 75-90% of TRAW's 99.53%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1411.37%
10Y equity/share CAGR above 1.5x TRAW's 100.00%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-77.60%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-28.05%
Negative 3Y equity/share growth while TRAW is at 100.24%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Positive asset growth while TRAW is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
13.37%
Positive BV/share change while TRAW is negative. John Neff sees a clear edge over a competitor losing equity.
-15.85%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
22.47%
R&D growth drastically higher vs. TRAW's 8.13%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-1.59%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.